nach oben

Current Infectious Disease Reports

Erschienen in:

01.08.2019 | Skin, Soft Tissue, Bone and Joint Infectious Disease (N Safdar and A Pop-Vicas, Section Editors)

Updates on Nocardia Skin and Soft Tissue Infections in Solid Organ Transplantation

verfasst von: Marion Hemmersbach-Miller, Jelena Catania, Jennifer L. Saullo

Erschienen in: Current Infectious Disease Reports | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Due to their immunocompromised status, solid organ transplant (SOT) recipients are at risk for Nocardia infections. These infections often necessitate early invasive diagnostics alongside prolonged, often combination antimicrobial therapy. This review summarizes the importance of this pathogen in skin and soft tissue infections (SSTIs) in SOT recipients inclusive of recently reported cases in the literature and an update on the epidemiology, diagnostics, and management.

Recent Findings

Six studies with 13 isolated SSTIs due to Nocardia have been published in the last 5 years in SOT recipients. The most common underlying type of transplant was kidney and time from transplantation to infection varied from 6 months to 16 years. Misdiagnosis was frequent. Available identified species included N. brasiliensis (2), N. farcinica (2), N. flavorosea (1), N. abscessus (1), N. anaemiae (1), N. asteroides (1), N. nova (1), and N. vinacea (1). Treatment choice and duration varied widely, and trimethoprim-sulfamethoxazole was utilized most often with no documented infection relapse.

Summary

Nocardia SSTIs can occur both in isolation and as a component of a disseminated infection. Overall, isolated Nocardia SSTIs are uncommon in SOT recipients and are often initially misdiagnosed. They present multiple challenges to the clinician including evaluation for potential co-pathogens and/or non-infectious processes and ruling out the presence of disseminated infection. While trimethoprim-sulfamethoxazole remains the agent of choice for management of most isolated SSTIs, therapy must be tailored to the individual patient based on species-specific susceptibility patterns and formal susceptibility testing, site(s) of infection, and patient tolerability.

Lerner PI. Nocardiosis. Clinical Infect Dis: Off Publ Infect Dis Soc Am. 1996;22(6):891–903 quiz 4-5.CrossRef

Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev. 2006;19(2):259–82. https://doi.org/10.1128/cmr.19.2.259-282.2006.CrossRef

Brown-Elliott BACP, Wallace RJ. Current status of Nocardia taxonomy and recommended identification methods. Clin Microbiol Newsl. 2015;37(4):25–32.CrossRef

Conville PS, Brown-Elliott BA, Smith T, Zelazny AM. The complexities of Nocardia taxonomy and identification. J Clin Microbiol. 2018;56(1). https://doi.org/10.1128/jcm.01419-17.

Woodworth MH, Saullo JL, Lantos PM, Cox GM, Stout JE. Increasing Nocardia incidence associated with bronchiectasis at a tertiary care center. Ann Am Thoracic Soc. 2017;14(3):347–54. https://doi.org/10.1513/AnnalsATS.201611-907OC.CrossRef

Wang HL, Seo YH, LaSala PR, Tarrand JJ, Han XY. Nocardiosis in 132 patients with cancer: microbiological and clinical analyses. Am J Clin Pathol. 2014;142(4):513–23. https://doi.org/10.1309/ajcpw84aftuwmhyu.CrossRefPubMed

Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2015;60(8):1176–83. https://doi.org/10.1093/cid/ciu1154. CrossRef

Rodriguez-Nava V, Durupt S, Chyderiotis S, Freydiere AM, Karsenty J, de Montclos M, et al. A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients. Med Microbiol Immunol. 2015;204(4):493–504. https://doi.org/10.1007/s00430-014-0360-3.CrossRefPubMed

Rosen LB, Rocha Pereira N, Figueiredo C, Fiske LC, Ressner RA, Hong JC, et al. Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2015;60(7):1017–25. https://doi.org/10.1093/cid/ciu968. CrossRef

10.

Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2007;44(2):204–12. https://doi.org/10.1086/510388. CrossRef

11.

Restrepo A, Clark NM. Nocardia infections in solid organ transplantation: Guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation. Clin Transpl 2019:e13509. doi:https://doi.org/10.1111/ctr.13509.

12.

Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis:Off Publ Infect Dis Soc Am. 2007;44(10):1307–14. https://doi.org/10.1086/514340. CrossRef

13.

Steinbrink J, Leavens J, Kauffman CA, Miceli MH. Manifestations and outcomes of nocardia infections: comparison of immunocompromised and nonimmunocompromised adult patients. Medicine. 2018;97(40):e12436. https://doi.org/10.1097/md.0000000000012436.CrossRefPubMedPubMedCentral

14.

Paige EK, Spelman D. Nocardiosis: 7-year experience at an Australian tertiary hospital. Intern Med J. 2019;49(3):373–9. https://doi.org/10.1111/imj.14068.CrossRefPubMed

15.

McGuinness SL, Whiting SE, Baird R, Currie BJ, Ralph AP, Anstey NM, et al. Nocardiosis in the tropical northern territory of Australia, 1997-2014. Open Forum Infectious Diseases. 2016;3(4):ofw208–ofw. https://doi.org/10.1093/ofid/ofw208.CrossRefPubMedPubMedCentral

16.

Hemmersbach-Miller M, Stout JE, Woodworth MH, Cox GM, Saullo JL. Nocardia infections in the transplanted host. Transpl Infect Dis: Off J Transpl Soc. 2018;20(4):e12902. https://doi.org/10.1111/tid.12902. CrossRef

17.

Haussaire D, Fournier PE, Djiguiba K, Moal V, Legris T, Purgus R, et al. Nocardiosis in the south of France during the last ten years. Int J Infect Dis : IJID : Off Publ Int Soc Infect Dis. 2017;57:13–20. https://doi.org/10.1016/j.ijid.2017.01.005.CrossRef

18.

Coussement J, Lebeaux D, van Delden C, Guillot H, Freund R, Marbus S, et al. Nocardia infection in solid organ transplant recipients: a multicenter European case-control study. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2016;63(3):338–45. https://doi.org/10.1093/cid/ciw241. CrossRef

19.

Lebeaux D, Freund R, van Delden C, Guillot H, Marbus SD, Matignon M, et al. Outcome and treatment of nocardiosis after solid organ transplantation: new insights from a European study. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2017;64(10):1396–405. https://doi.org/10.1093/cid/cix124. CrossRef

20.

Le Coustumier EM, Denes E, Martin C, Weinbreck P. Nocardiosis: a retrospective case series of 19 patients. Rev Med Interne. 2017;38(2):81–9. https://doi.org/10.1016/j.revmed.2016.08.015.CrossRefPubMed

21.

Shrestha S, Kanellis J, Korman T, Polkinghorne KR, Brown F, Yii M, et al. Different faces of Nocardia infection in renal transplant recipients. Nephrology (Carlton, Vic). 2016;21(3):254–60. https://doi.org/10.1111/nep.12585.CrossRef

22.

Kim YK, Sung H, Jung J, Yu SN, Lee JY, Kim SH, et al. Impact of immune status on the clinical characteristics and treatment outcomes of nocardiosis. Diagn Microbiol Infect Dis. 2016;85(4):482–7. https://doi.org/10.1016/j.diagmicrobio.2016.05.004.CrossRefPubMed

23.

Koerner MM, El-Banayosy A, Schulz U, Zeriouh M, Koerfer R, Tenderich G, et al. Nocardiosis in heart transplant recipients. The Heart Surgery Forum. 2015;18(6):E250–2. https://doi.org/10.1532/hsf.1372. CrossRefPubMed

24.

Herzog AL, Wanner C, Lopau K. Successful short-term intravenous treatment of disseminated Nocardia farcinica infection with severe hyponatremia after kidney transplantation: a case report. Transplant Proc. 2016;48(9):3115–9. https://doi.org/10.1016/j.transproceed.2016.04.004.CrossRefPubMed

25.

Arze S, Arze L, Abecia C. Post-transplantation infections in Bolivia. Transplant Proc. 2016;48(2):646–53. https://doi.org/10.1016/j.transproceed.2016.02.049.CrossRefPubMed

26.

Kim YK, Oh JR, Choi HK, Kim HY, Park SD, Uh Y. Primary cutaneous nocardiosis caused by Nocardia nova in a kidney transplant recipient. J Med Microbiol. 2014;63(Pt 1:140–3. https://doi.org/10.1099/jmm.0.054239-0.CrossRefPubMed

27.

Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601–14. https://doi.org/10.1056/NEJMra064928.CrossRef

28.

Roberts SA, Franklin JC, Mijch A, Spelman D. Nocardia infection in heart-lung transplant recipients at Alfred Hospital, Melbourne, Australia, 1989-1998. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2000;31(4):968–72. https://doi.org/10.1086/318150. CrossRef

29.

Lebeaux D, Morelon E, Suarez F, Lanternier F, Scemla A, Frange P, et al. Nocardiosis in transplant recipients. Eur J Clin Microbiol Infect Dis : Off Publ Eur Soc Clin Microbiol. 2014;33(5):689–702. https://doi.org/10.1007/s10096-013-2015-5. CrossRef

30.

Santos M, Gil-Brusola A, Morales P. Infection by Nocardia in solid organ transplantation: thirty years of experience. Transplant Proc. 2011;43(6):2141–4. https://doi.org/10.1016/j.transproceed.2011.06.065.CrossRefPubMed

31.

Majeed A, Beatty N, Iftikhar A, Mushtaq A, Fisher J, Gaynor P, et al. A 20-year experience with nocardiosis in solid organ transplant (SOT) recipients in the southwestern United States: a single-center study. Transpl Infect Dis : Off J Transpl Soc. 2018;20(4):e12904. https://doi.org/10.1111/tid.12904.CrossRef

32.

Valdezate S, Garrido N, Carrasco G, Medina-Pascual MJ, Villalon P, Navarro AM, et al. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother. 2017;72(3):754–61. https://doi.org/10.1093/jac/dkw489.CrossRefPubMed

33.

Poonyagariyagorn HK, Gershman A, Avery R, Minai O, Blazey H, Asamoto K, et al. Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients. Transpl Infect Dis :Off J Transpl Soc. 2008;10(6):403–8. https://doi.org/10.1111/j.1399-3062.2008.00338.x. CrossRef

34.

Schlaberg R, Fisher MA, Hanson KE. Susceptibility profiles of Nocardia isolates based on current taxonomy. Antimicrob Agents Chemother. 2014;58(2):795–800. https://doi.org/10.1128/aac.01531-13.CrossRefPubMedPubMedCentral

35.

Wallace RJ Jr, Tsukamura M, Brown BA, Brown J, Steingrube VA, Zhang YS, et al. Cefotaxime-resistant Nocardia asteroides strains are isolates of the controversial species Nocardia farcinica. J Clin Microbiol. 1990;28(12):2726–32.

36.

Ayoade F, Mada P, Joel Chandranesan AS, Alam M. Sporotrichoid skin infection caused by Nocardia brasiliensis in a kidney transplant patient. Diseases (Basel, Switzerland). 2018;6(3). https://doi.org/10.3390/diseases6030068.CrossRef

37.

Chikowski RE, Sprigle AM, Krishna SM, Nunley JR. Primary cutaneous Nocardia vinacea in a renal transplant recipient: report of a rare case and review of the literature. Clin Exp Dermatol. 2014;39(4):534–6. https://doi.org/10.1111/ced.12303.CrossRefPubMed

38.

Atzori LPA, Pau M. Cutaneous nocardiosis. SOJ Microbiol Infect Dis. 2014;2(1). https://doi.org/10.15226/sojmid.2014.00110.

39.

Khadka P, Shah DS. Primary cutaneous nocardiosis: a diagnosis of consideration in a renal transplant recipient. BMC Clin Pathol. 2018;18:8. https://doi.org/10.1186/s12907-018-0075-2.CrossRefPubMedPubMedCentral

40.

McGhie T, Fader R, Carpenter J, Brown-Elliott BA, Vasireddy R, Wallace RJ, Jr. Nocardia neocaledoniensis [corrected] as a cause of skin and soft tissue infection. J Clin Microbiol 2012;50(9):3139–3140. doi:https://doi.org/10.1128/jcm.00559-12.CrossRef

41.

Welsh O, Salinas-Carmona MC, Brown-Elliott BA, Smith T, Cardenas-De La Garza JA, Wallace RJ Jr. Disseminated actinomycetoma due to Nocardia wallacei. Int J Dermatol. 2018;57(5):580–2. https://doi.org/10.1111/ijd.13909. CrossRef

42.

Dua J, Clayton R. First case report of Nocardia veterana causing nodular lymphangitis in an immunocompromised host. Australas J Dermatol. 2014;55(3):e48–50. https://doi.org/10.1111/ajd.12043.CrossRefPubMed

43.

Escudero-Jimenez A, Saez-Nieto JA, Turowicz M, Bartolome-Alvarez J. Skin infection after infiltration by Nocardia cerradoensis. Enferm Infecc Microbiol Clin. 2016;34(5):325–6. https://doi.org/10.1016/j.eimc.2015.07.015. CrossRefPubMed

44.

Baek JO, Kim JS, Lee SK, Jeong JH, Lee MJ, Seo IH. Two cases of primary cutaneous nocardiosis caused by intralesional injection. Dermatol Ther. 2019;32(1):e12775. https://doi.org/10.1111/dth.12775.CrossRefPubMed

45.

Kalb RE, Kaplan MH, Grossman ME. Cutaneous nocardiosis. Case reports and review. J Am Acad Dermatol. 1985;13(1):125–33.CrossRef

46.

Naldi L, Venturuzzo A, Invernizzi P. Dermatological complications after solid organ transplantation. Clin Rev Allergy Immunol. 2018;54(1):185–212. https://doi.org/10.1007/s12016-017-8657-9.CrossRefPubMed

47.

Smego RA, Castiglia M, Asperilla MO. Lymphocutaneous syndrome - a review of non-sporothrix causes. Medicine. 1999;78(1):38–63. https://doi.org/10.1097/00005792-199901000-00004.CrossRef

48.

Abudu B, Cohen PR. Sporotrichoid keratoacanthomas: case report and review of neoplasms presenting in a sporotrichoid pattern. Cureus. 2018;10(8). https://doi.org/10.7759/cureus.3196.

49.

van de Sande WW. Global burden of human mycetoma: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2013;7(11):e2550. https://doi.org/10.1371/journal.pntd.0002550.CrossRefPubMedPubMedCentral

50.

Verma P, Jha A. Mycetoma: reviewing a neglected disease. Clin Exp Dermatol. 2019;44(2):123–9. https://doi.org/10.1111/ced.13642.CrossRefPubMed

51.

McNeil MM, Brown JM. The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev. 1994;7(3):357–417.CrossRef

52.

Ricci JA, Weil AA, Eberlin KR. Necrotizing cutaneous nocardiosis of the hand: a case report and review of the literature. J Hand Microsurg. 2015;7(1):224–7. https://doi.org/10.1007/s12593-015-0173-7.CrossRefPubMedPubMedCentral

53.

Lin YC, Huang ZY, Sun JR, Yu CM, Wang CH. First case report of Nocardia brasiliensis infection causing necrotizing fasciitis in an immunocompetent patient. J Microbiol Immunol Infect. 2016;49(5):824–5. https://doi.org/10.1016/j.jmii.2016.03.007.CrossRefPubMed

54.

George SJ, Rivera AM, Hsu S. Disseminated cutaneous nocardiosis mimicking cellulitis and erythema nodosum. Dermatol Online J. 2006;12(7):13.PubMed

55.

Desai M, Imran M, Irum A, Magadan J 3rd. Primary cutaneous nocardiosis in a patient taking adalimumab therapy for Crohn’s disease. Kans J Med. 2017;10(1):20–1.CrossRef

56.

Burke VE, Lopez FA. Approach to skin and soft tissue infections in non-HIV immunocompromised hosts. Curr Opin Infect Dis. 2017;30(4):354–63. https://doi.org/10.1097/qco.0000000000000378.CrossRefPubMed

57.

Anagnostou T, Arvanitis M, Kourkoumpetis TK, Desalermos A, Carneiro HA, Mylonakis E. Nocardiosis of the central nervous system: experience from a general hospital and review of 84 cases from the literature. Medicine. 2014;93(1):19–32. https://doi.org/10.1097/md.0000000000000012.CrossRefPubMedPubMedCentral

58.

Procop GWCD, Hall GS, Janda WM, Koneman EW, Schreckenberger PC, Woods GL. Color atlas and textbook of diagnostic microbiology. 7th ed; 2017.

59.

Mishra SK, Gordon RE, Barnett DA. Identification of nocardiae and streptomycetes of medical importance. J Clin Microbiol. 1980;11(6):728–36.PubMedPubMedCentral

60.

Body BA, Beard MA, Slechta ES, Hanson KE, Barker AP, Babady NE, et al. Evaluation of the Vitek MS v3.0 matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of Mycobacterium and Nocardia species. J Clin Microbiol. 2018;56(6):e00237–18. https://doi.org/10.1128/jcm.00237-18.CrossRef

61.

Blosser SJ, Drake SK, Andrasko JL, Henderson CM, Kamboj K, Antonara S, et al. Multicenter matrix-assisted laser desorption ionization-time of flight mass spectrometry study for identification of clinically relevant Nocardia spp. J Clin Microbiol. 2016;54(5):1251–8. https://doi.org/10.1128/jcm.02942-15.CrossRefPubMedPubMedCentral

62.

Wayne P. CLSI. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomyces. 1st Edition2018.

63.

Wayne P. CLSI. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomyces. 3rd Edition2018.

64.

Conville PS, Brown-Elliott BA, Wallace RJ Jr, Witebsky FG, Koziol D, Hall GS, et al. Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species. J Clin Microbiol. 2012;50(4):1270–80. https://doi.org/10.1128/jcm.00994-11.CrossRef

65.

Ho JMW, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ : Canad Med Assoc J = J l’Assoc Med Canad. 2011;183(16):1851–8. https://doi.org/10.1503/cmaj.111152.CrossRef

66.

Uhde KB, Pathak S, McCullum I Jr, Jannat-Khah DP, Shadomy SV, Dykewicz CA, et al. Antimicrobial-resistant Nocardia isolates, United States, 1995-2004. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2010;51(12):1445–8. https://doi.org/10.1086/657399. CrossRef

67.

Lai CC, Liu WL, Ko WC, Chen YH, Tang HJ, Huang YT, et al. Antimicrobial-resistant Nocardia isolates, Taiwan, 1998-2009. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;52(6):833–5. https://doi.org/10.1093/cid/ciq255. CrossRef

68.

Larruskain J, Idigoras P, Marimon JM, Perez-Trallero E. Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents. Antimicrob Agents Chemother. 2011;55(6):2995–8. https://doi.org/10.1128/aac.01279-10.CrossRefPubMedPubMedCentral

69.

Brown-Elliott BA, Biehle J, Conville PS, Cohen S, Saubolle M, Sussland D, et al. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey. J Clin Microbiol. 2012;50(3):670–2. https://doi.org/10.1128/jcm.06243-11.CrossRef

70.

Brown-Elliott BA, Killingley J, Vasireddy S, Bridge L, Wallace RJ Jr. In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing mycobacteria and Nocardia by use of broth microdilution and etest. J Clin Microbiol. 2016;54(6):1586–92. https://doi.org/10.1128/jcm.00298-16.CrossRef

71.

Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet (London, England). 2001;358(9297):1975–82. https://doi.org/10.1016/s0140-6736(01)06964-1.CrossRef

72.

Pfizer Inc. Zyvox package insert. New York: Pfizer Inc.; 2013.

73.

Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES, Birmingham MC, et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2003;36(3):313–8. https://doi.org/10.1086/345907.

74.

De La Cruz O, Minces LR, Silveira FP. Experience with linezolid for the treatment of nocardiosis in organ transplant recipients. The Journal of infection. 2015;70(1):44–51. https://doi.org/10.1016/j.jinf.2014.08.010.CrossRef

75.

Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of tedizolid against isolates of Nocardia. Antimicrob Agents Chemother. 2017;61(12). https://doi.org/10.1128/aac.01537-17.

76.

Roger C, Roberts JA, Muller L. Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin Pharmacokinet. 2018;57(5):559–75. https://doi.org/10.1007/s40262-017-0601-x.CrossRefPubMed

77.

King CT, Chapman SW, Butkus DE. Recurrent nocardiosis in a renal transplant recipient. South Med J. 1993;86(2):225–8.CrossRef

78.

Palmer DL, Harvey RL, Wheeler JK. Diagnostic and therapeutic considerations in Nocardia asteroides infection. Medicine. 1974;53(5):391–401.CrossRef

79.

Wallace RJ Jr, Septimus EJ, Williams TW Jr, Conklin RH, Satterwhite TK, Bushby MB, et al. Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia. Rev Infect Dis. 1982;4(2):315–25.CrossRef

80.

Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection. 2010;38(2):89–97. https://doi.org/10.1007/s15010-009-9193-9.CrossRefPubMed

Titel: Updates on Nocardia Skin and Soft Tissue Infections in Solid Organ Transplantation
verfasst von: Marion Hemmersbach-Miller
Jelena Catania
Jennifer L. Saullo
Publikationsdatum: 01.08.2019
Verlag: Springer US
Erschienen in: Current Infectious Disease Reports / Ausgabe 8/2019
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-019-0684-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen